

Vaccine Allied Biologics

Letter to Editor

One of the themes that are longly born in mind, those concerning "Vaccine versus Probiotics". Then, if it is feasible to raise a question such as "Could we consider Probiotic as a vaccine, since they have an in-common indication, applications and/or attributes (Table 1). The common affairs are rather more than the different affairs. Thus, I think that they are forms of bio-therapeutics owning vaccine like potentials or one can say that they are vaccine-allied biologics.

Letter to the Editor

Volume 2 Issue 2 - 2016

Ibrahim MSAW Shnawa*

University of Qasim, Iraq

*Corresponding author: Ibrahim MSAW Shnawa, College of Biotechnology, University of Qasim, Qasim, Babylon, Iraq, Email: ibrahimshnawa3@gmail.com

Received: March 30, 2016 | Published: April 07, 2016

Table 1: Characteristics of vaccine versus probiotics.

Vaccines	Probiotics	Features
Pathogens or their subunits	Certain commensal bacteria	Starter
Specific in most cases	Nonspecific in most cases	Specificity
Stringent for human favor	Less stringent for human favor	Evaluation attitude
Needs special dispensing menu	Drug-like dispensing menu	Dispensing
Specific mostly	Nonspecific, mostly	Specificity
Immunoprphylaction	Biotherapy of various immune defects in man and animals	Indication
Massive use rather than individual cases	On individual basis more than massive	Use
Infectious, epidemic and pandemic threat or on travel to epidemic or endemic areas	Infectious and non-infectious	Disease nature
Based on affinity of B and T memory cells	Bacteriocin, immunomodulatory, anticancerous	Mode of action
Mild short duration like fever and ill	No appearent side effect	Side Effect
Due to vaccine or host born causes	Due to probiotic or host born causes	Failure

References

1. Banker DD (1980) Modren Practice In Immunization. Popular Prakshan, Bombay, India, pp. 384.
2. Kaufmann SHE (2004) Novel Vaccination Strategies. Wiley-VCH, Germany, pp. 670.
3. Kumar H, Salminen S, Vergagen H, Rowland I, Heimbach J, et al. (2015) Probiotics and prebiotics road to market. Curr Opin Biotech 32: 99-103.
4. Quigley EMM (2016) Leaky gut-Concept or clinical entity. Curr Opin Gastroenterol 32(2): 74-79.